MAPT and Alzheimer disease: Cerebrospinal fluid (CSF)-based biomarkers for AD—low levels of the 42-amino acid form of Aβ (Aβ42) and elevated levels of phosphorylated and total tau (P-tau and T-tau, respectively)—were also reviewed (here collectively referred to as “CSF AD biomarkers”) [9].